> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sellas Gains Orphan Status for Multiple Myeloma Drug
- URL: https://www.fdaweb.com/sellas-gains-orphan-status-for-multiple-myeloma-drug/
- Published: 2018-05-10T12:00:00.000Z
- Updated: 2026-09-15T00:04:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141409

FDA has granted Sellas Life Sciences Group an orphan drug designation for its novel drug candidate, galinpepimut-S (GPS), for treating multiple myeloma. GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in several tumor types, according to the company. Sellas says it has reported median progression-free survival of 23.6 months in the high-risk multiple myeloma disease setting, compared to historical outcomes in other patient cohorts of around 12 months. GPS has also been shown to stimulate “time-dependent and robust CD4+ T cell or CD8+ T cell immune responses as well as multifunctional cross-epitope T cell reactivity,” it says.